Ignite Creation Date:
2025-12-25 @ 2:57 AM
Ignite Modification Date:
2025-12-31 @ 11:51 AM
Study NCT ID:
NCT05463133
Status:
RECRUITING
Last Update Posted:
2025-06-04
First Post:
2022-07-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-08
Start Date Type:
ACTUAL
Primary Completion Date:
2032-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-07-15
First Submit QC Date:
None
Study First Post Date:
2022-07-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-03
Last Update Post Date:
2025-06-04
Last Update Post Date Type:
ACTUAL